17 The effect of postoperative ketorolac on hemoglobin and postoperative pain control after vaginal surgery S. Shah, D. Thompson, H. Goldstein OB/GYN, Christiana Care Health System, Newark, DE OBJECTIVES: Ketorolac is an appealing alternative to narcotics in postoperative pain management. However, there is concern for postoperative bleeding with its use. Postoperative bleeding after vaginal reconstructive surgery is a well-established complication and can present acutely secondary to bleeding from the vaginal cuff, vascular pedicles or with deteriorating vital signs indicative of a retroperitoneal hematoma. With conflicting evidence in the literature on postoperative bleeding with ketorolac use, we sought to evaluate and compare the effect of ketorolac on postoperative bleeding and to assess its impact on postoperative pain control. MATERIALS AND METHODS: This is a retrospective cohort study of women who had vaginal reconstructive surgery at Christiana Care Health System between January 1, 2014 and December 31, 2014. Patients were identified through CPT codes for vaginal reconstructive surgeries that required an inpatient stay. Data on preoperative and postoperative hemoglobin levels as well as total narcotic use was collected for each patient. The total narcotic use was then converted to IV hydromorphone using an opioid equivalence conversion. Data analysis was performed using a chi-square test and unpaired t-test to assess the differences in demographics and clinical characteristics of patients who received ketorolac and those who did not receive ketorolac. Multiple regression and linear regression analyses were performed to assess the effect of ketorolac use on hemoglobin and total narcotic use. RESULTS: One hundred twenty-nine vaginal surgery cases were identified in the study period. Of those cases, 54 (41.9%) patients received ketorolac and 75 (58.1%) patients did not receive ketorolac. There was no statistically significant difference in mean narcotic use between the ketorolac group and the no ketorolac group (3.85 mg vs 3.0 mg, p ¼ 0.194). Total ketorolac use was not associated with an increase in estimated blood loss (p ¼ 0.169). Among patients who received ketorolac, there was no significant difference in pre-operative and post-operative hemoglobin when adjusting for estimated blood loss. One patient had a retroperitoneal hematoma and had not received ketorolac. One patient required a blood transfusion and had not received ketorolac. CONCLUSION: This study found that that there was no difference in change in hemoglobin with the use of ketorolac. The total amount of narcotic use was not decreased in patients who received ketorolac postoperatively for additional pain control.
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